DRTE It is not really a Biotech or Pharma Co., but a software Co.<g>
However, its major customers are large, multinational Pharma Cos., including: ABT, AGN, AZN, AVE, BMY, CLL, DNPCY.PK, LLY, FRX, NVS, PFE,TDCHF.PK,TINLY.PK, WYE and a few others.<g>
More than half of its 2001 revenues reportedly came from its two largest clients, PFE and BMY.
The company had an "upgrade" on June 3 from Grunthal to Near Term "Outperform" from Near Term "Perform".<g>
It is likely that the earning report to be announced on July 25 will be better than last year's since in the June Q of 2001 the Co. had a "non-recurring" charge of $15.75M <g> (All the other Qs including the last one have been on the black)
At any rate, what it seems interesting is that the company afte the last five days of steady decline may have found support at the 7.50 level since it is up today in spite of the general market.<g>
siliconinvestor.com
Bernard |
